Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 10Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1First-line Treatment 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Gemcitabine 7Cystectomy 5Cisplatin 5durvalumab 4Neoadjuvant Therapy 4Mitomycin 4atezolizumab 3Transurethral Resection of Bladder 3Nivolumab 3Epirubicin 3Chemoradiotherapy 3BCG Vaccine 3Anesthesia, Spinal 3tislelizumab 2disitamab vedotin 2catumaxomab 2Vitamin E 2Urinary Diversion 2Sunitinib 2Selenium 2Robotic Surgical Procedures 2Multiparametric Magnetic Resonance Imaging 2Magnetic Resonance Imaging 2Immunohistochemistry 2Fentanyl 2Docetaxel 2Diathermy 2Cystoscopy 2Chemoprevention 2BCG Connaught 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Urinary Bladder Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03762161 2022-03-10

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

University of Kansas Medical Center

Phase 2 Unknown
22 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡